Human genetic engineering is coming. We must discuss the social and political implications now
By Samira Kiani,
The Globe and Mail
| 05. 06. 2022
photo by the He Lab
In October, 2018, I was invited to a secret meeting in Guangzhou, China. I was there because of my work as a genetic scientist who uses the CRISPR technology to cut and splice DNA, an approach to genetic engineering that has come to the forefront over the past decade. I don’t think it’s an overstatement to say that CRISPR, a precise and efficient tool that allows us to “edit” genes, is on the verge of altering the course of human history to an extent far greater than the recent “disruptions” catalyzed by internet technology. If you think digital surveillance tools are frightening in the hands of autocracy, consider the power to bend the human genome to one’s will. CRISPR provides that power. To use another analogy, the ability to edit genes with surgical precision is a scientific discovery on par with nuclear fission – while there may be beneficial applications, it is by nature seductive to our darkest impulses.
Because of CRISPR’s unknown risks, its use has been limited to certain applications by longstanding consensus...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...